DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer

Overview

Journal PPAR Res

Publisher Wiley

Date 2021 Feb 22

PMID 33613670

Citations 7

Authors

Qianqian Zhao

Jie Zhong

Ping Lu

Xiao Feng

Ying Han

Chenqi Ling

Wenke Guo

Weijin Zhou

Fudong Yu

Affiliations

Soon will be listed here.

Abstract

Ovarian carcinoma (OV) is a lethal gynecological malignancy. Most OV patients develop resistance to platinum-based chemotherapy and recurrence. Peroxisome proliferator-activated receptors (PPARs) are the ligand activating transcription factor of the nuclear receptor superfamily. PPARs as important transcriptional regulators regulate important physiological processes such as lipid metabolism, inflammation, and wound healing. Several reports point out that PPARs can also have an effect on the sensitivity of tumor cells to platinum-based chemotherapy drugs. However, the role of PPAR-target related genes (PPAR-TRGs) in chemotherapeutic resistance of OV remains unclear. The present study is aimed at optimizing candidate genes by integrating platinum-chemotherapy expression data and PPAR family genes with their targets. The gene expression profiles were obtained from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. A total of 4 genes (, , , and ) were the candidate differentially expressed genes (DEGs) of PPAR-TRGs with platinum chemosensitivity. After conducting numerous survival analyses using different cohorts, we found that only the upexpression of has important significance with the poor prognosis of OV patients. Meanwhile, is detected in plasma and enriched in neutrophil and monocyte cells of the blood. We further found that there were significant correlations between expression and the levels of CD4+ T cell infiltration, dendritic cell infiltration, and neutrophil infiltration in OV. In addition, we verified the expression level of in OV cell lines treated with platinum drugs and found that is potentially responsive to platinum drugs. In conclusion, is potentially associated with immune cell infiltration and represents a valuable prognostic biomarker in ovarian cancer patients.

Citing Articles

Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids.

Cai X, Li Y, Zheng J, Liu L, Jiao Z, Lin J Front Oncol. 2024; 13:1291559.

PMID: 38370348 PMC: 10869451. DOI: 10.3389/fonc.2023.1291559.

DOCK4 is a Novel Prognostic Biomarker and Correlated with Immune Infiltrates in Colon Adenocarcinoma.

Xie X, Lu Y, Wang B, Yin X, Chen J Comb Chem High Throughput Screen. 2023; 27(8):1119-1130.

PMID: 37702239 DOI: 10.2174/1386207326666230912094101.

Comprehensive Analysis Identifies the PPAR-Targeted Genes Associated with Ovarian Cancer Prognosis and Tumor Microenvironment.

Leng X, Wang G, Yin H, Wei F, Zeng K, Zhang Y PPAR Res. 2023; 2023:6637414.

PMID: 37213709 PMC: 10195182. DOI: 10.1155/2023/6637414.

MiR-26a-5p regulates proliferation, apoptosis, migration and invasion via inhibiting hydroxysteroid dehydrogenase like-2 in cervical cancer cell.

Li M, Xiao Y, Liu M, Ning Q, Xiang Z, Zheng X BMC Cancer. 2022; 22(1):876.

PMID: 35948893 PMC: 9367141. DOI: 10.1186/s12885-022-09970-x.

PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.

Sha Y, Wu J, Paul B, Zhao Y, Mathews P, Li Z Cancer Lett. 2022; 545:215832.

PMID: 35872263 PMC: 10355274. DOI: 10.1016/j.canlet.2022.215832.

References

Hiramoto K, Negishi M, Katoh H . Dock4 is regulated by RhoG and promotes Rac-dependent cell migration. Exp Cell Res. 2006; 312(20):4205-16. DOI: 10.1016/j.yexcr.2006.09.006. View

Mirza A, Althagafi I, Shamshad H . Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem. 2019; 166:502-513. DOI: 10.1016/j.ejmech.2019.01.067. View

Westbrook J, Wood S, Cairns D, McMahon K, Gahlaut R, Thygesen H . Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. J Pathol. 2018; 247(3):381-391. PMC: 6618075. DOI: 10.1002/path.5197. View

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

Sato E, Olson S, Ahn J, Bundy B, Nishikawa H, Qian F . Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51):18538-43. PMC: 1311741. DOI: 10.1073/pnas.0509182102. View

Nomura S, Nakajima A, Ishimine S, Matsuhashi N, Kadowaki T, Kaminishi M . Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. J Exp Clin Cancer Res. 2006; 25(3):443-8. View

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang A . Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016; 48(7):758-67. DOI: 10.1038/ng.3573. View

Girnun G, Naseri E, Vafai S, Qu L, Szwaya J, Bronson R . Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell. 2007; 11(5):395-406. PMC: 2564847. DOI: 10.1016/j.ccr.2007.02.025. View

10.

Fang L, Zhang M, Li Y, Liu Y, Cui Q, Wang N . PPARgene: A Database of Experimentally Verified and Computationally Predicted PPAR Target Genes. PPAR Res. 2016; 2016:6042162. PMC: 4842375. DOI: 10.1155/2016/6042162. View

11.

Kossai M, Leary A, Scoazec J, Genestie C . Ovarian Cancer: A Heterogeneous Disease. Pathobiology. 2017; 85(1-2):41-49. DOI: 10.1159/000479006. View

12.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

13.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

14.

Yang P, Wang J, Cheng X, Chen J, Zhu H, Li X . PPAR- Ligand Inhibits Nasopharyngeal Carcinoma Cell Proliferation and Metastasis by Regulating E2F2. PPAR Res. 2019; 2019:8679271. PMC: 6699258. DOI: 10.1155/2019/8679271. View

15.

Wagner K, Wagner N . Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2009; 125(3):423-35. DOI: 10.1016/j.pharmthera.2009.12.001. View

16.

Kobayashi M, Harada K, Negishi M, Katoh H . Dock4 forms a complex with SH3YL1 and regulates cancer cell migration. Cell Signal. 2014; 26(5):1082-8. DOI: 10.1016/j.cellsig.2014.01.027. View

17.

Yu J, Tai Y, Jin Y, Hammell M, Wilkinson J, Roe J . TGF-β/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis. Genes Dev. 2015; 29(3):250-61. PMC: 4318142. DOI: 10.1101/gad.248963.114. View

18.

Hwang W, Adams S, Tahirovic E, Hagemann I, Coukos G . Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2011; 124(2):192-8. PMC: 3298445. DOI: 10.1016/j.ygyno.2011.09.039. View

19.

Chang W, Lai A . The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia. Ann N Y Acad Sci. 2019; 1448(1):65-82. DOI: 10.1111/nyas.14170. View

20.

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View